pxt3003
Small moleculeexperimental
Clinical trial activity
4 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01401257)
Timeline
Indications
Mechanism of action
- Peripheral myelin protein 22INHIBITOR
PMP22 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pxt3003
- pxt3003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05092841 | Phase 3 | Sep 28, 2021 | Tasly Pharmaceuticals, Inc. |
| NCT03023540 | Phase 3 | Mar 7, 2017 | Aix-University of Marseille, INC Research, Pharnext SA, Seton Hall University, Synteract, Inc., University of Amsterdam, University of Manchester, University of Munster |
| NCT02579759 | Phase 3 | Dec 1, 2015 | Aix-University of Marseille, Katholieke Universiteit Leuven, Pharnext SA, Salford Royal Foundation NHS Trust, St. Louis University, University of Amsterdam, University of Munster |
| NCT01401257 | Phase 2 | Dec 1, 2010 | Pharnext SA |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pharnext SA | For profit | 3 | 3 | 2 | 2010 |
| Aix-University of Marseille | Academic/Hospital | 2 | 0 | 1 | 2015 |
| University of Amsterdam | Academic/Hospital | 2 | 0 | 1 | 2015 |
| University of Munster | Academic/Hospital | 2 | 0 | 1 | 2015 |
| INC Research | For profit | 1 | 0 | 1 | 2017 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Salford Royal Foundation NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Seton Hall University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| St. Louis University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Synteract, Inc. | For profit | 1 | 0 | 1 | 2017 |
| Tasly Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2021 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2017 |
12 organizations
Page 1 / 1